1.00

2.04% 0.02

After Hours: 1.01 0.01 +1.00%

Iterum Therapeutics Plc (ITRM)

Overview News Price History Financials Why ITRM Down? Discussions Forecast Stock Split

Iterum Therapeutics Plc stock is traded at $1.00, with a volume of 568.16K. It is up +2.04% in the last 24 hours and down -10.71% over the past month. Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Previous Close:

$0.98

Open:

$0.976

24h Volume:

568.16K

Relative Volume:

1.33

Market Cap:

$40.00M

Revenue:

Net Income/Loss:

$-35.58M

P/E Ratio:

-0.3774

EPS:

-2.65

Net Cash Flow:

$-42.82M

1W Performance:

+7.32%

1M Performance:

-10.71%

6M Performance:

-50.50%

1Y Performance:

-22.48%

1-Day Range:

$0.976

$1.05

1-Week Range:

$0.92

$1.05

52-Week Range:

$0.808

$3.02

Iterum Therapeutics Plc Stock (ITRM) Company Profile

Name

Iterum Therapeutics Plc

Sector

Healthcare (1170)

Industry

Biotechnology (671)

Phone

(872) 225-6077

Address

3 DUBLIN LANDINGS, DUBLIN 1

Employee

Twitter

Next Earnings Date

2025-02-07

Latest SEC Filings

ITRM's Discussions on Twitter

Compare ITRM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ITRM Iterum Therapeutics Plc	1.00	37.24M	0	-35.58M	-42.82M	-2.65
ONC Beone Medicines Ltd Adr	245.58	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	64.44B	14.09B	4.50B	2.96B	39.28

Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-21	Upgrade	Gabelli & Co	Sell → Hold
Mar-15-21	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-02-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jan-21-20	Downgrade	Gabelli & Co	Buy → Sell
Dec-11-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-21-19	Initiated	H.C. Wainwright	Buy

View All

Iterum Therapeutics Plc Stock (ITRM) Latest News

May 19, 2025

Pfizer grants Iterum payment extension for FDA-approved antibiotic By Investing.com - Investing.com South Africa

May 19, 2025

Pfizer grants Iterum payment extension for FDA-approved antibiotic - Investing.com Australia

May 19, 2025

Iterum Therapeutics Announces Extension of Term of Promissory No - GuruFocus

May 19, 2025

Iterum Therapeutics (ITRM) Extends $20M Payment Deadline with Pf - GuruFocus

May 19, 2025

Iterum Therapeutics Announces Extension of Term of Promissory Note | ITRM Stock News - GuruFocus

May 19, 2025

Iterum Therapeutics Announces Extension of Term of Promissory Note - The Manila Times

May 19, 2025

Iterum Therapeutics Announces Extension of $20 Million Regulatory Milestone Payment Deadline with Pfizer to 2029 - Nasdaq

May 19, 2025

Iterum Gains 3-Year Extension on $20M Pfizer Payment, Strengthens ORLYNVAH Launch Strategy - Stock Titan

May 19, 2025

Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026 - MSN

May 19, 2025

May 16, 2025

When Will Iterum Therapeutics plc (NASDAQ:ITRM) Become Profitable? - simplywall.st

May 16, 2025

May 14, 2025

Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025